Key result
Post-approval observational studies evaluate real-world NOAC adherence for stroke prevention in AF.
Why the study?
Adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation after approval has not been comprehensively evaluated in observational studies.
This paper evaluates adherence to non-vitamin-K antagonist oral anticoagulants in real-world observational studies of patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Real-world NOAC adherence data in AF warrant caution in practice; leaves open need for trials to identify modifiable targets.
The landmark randomized clinical trials (RCTs) of non-vitamin-K antagonist oral anticoagulants (NOACs, i.e. dabigatran, rivaroxaban, apixaban and edoxaban) for stroke prevention in patients with no...
No takes yet. Share an insight, caveat, or question.
Potpara et al. (2017) studied this question. Non-vitamin-K antagonist oral anticoagulant adherence in patients with atrial fibrillation is evaluated in post-approval observational studies to assess real-world stroke prevention.
Synapse has enriched 10 related papers. Consider them for comparative context: